stockrow
Saturday 7 November 2026
Export OKUR’s income statement to Excel — free account
OnKure Therapeutics, Inc.
OKUR Healthcare Biotechnology
- EPS
- +67.2%
- Free cash flow
- +22.1%
Quarter to September 2026, against a year earlier
2.79
0.26
+10.28%
Follow OKUR
Alert me
OnKure Therapeutics, Inc. (OKUR) P/E ratio
OnKure Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NBP NovaBridge Biosciences compare | n/m |
| VYGR Voyager Therapeutics, Inc. compare | n/m |
| IMUX Immunic, Inc. compare | n/m |
| AVXL Anavex Life Sciences Corp. compare | n/m |
| OTLK Outlook Therapeutics, Inc. compare | n/m |
| HURA TuHURA Biosciences, Inc. compare | n/m |
| ANIX ANIXA BIOSCIENCES INC compare | n/m |
| NRXP NRx Pharmaceuticals, Inc. compare | n/m |
| OKUR OnKure Therapeutics, Inc. | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)